Hindustan Bio Sciences Ltd (532041)
Latest quarterly results (Q1 FY27)
In its latest reported quarter, Q1 FY27, Hindustan Bio's revenue was ₹0.0 Cr (-100.0% year on year), and net profit ₹-0.1 Cr (against a profit a year earlier).
| Q1 FY27 (₹ Cr) | Value | YoY vs Q1 FY26 | QoQ |
|---|---|---|---|
| Revenue | ₹0.0 | -100.0% | — |
| Operating profit | ₹-0.1 | — | loss widened |
| Net profit | ₹-0.1 | to loss | loss narrowed |
| EPS (₹) | -0.11 | to loss | loss narrowed |
📢 Recent Corporate Announcements
Hindustan Bio Sciences Limited held its 34th Annual General Meeting on September 30, 2026, with 39 shareholders present (4 promoter, 35 public). Key resolutions tabled included the adoption of FY26 financial statements, the reappointment of retiring director Smt. Uma Jampana, and a special resolution to consider a Scheme of Reduction of Share Capital. Voting was conducted via remote e-voting and physical poll, with results expected within 2 working days. The company has a tiny market cap of ₹7 Cr and recorded zero revenue in recent quarters.
- 34th AGM held on September 30, 2026, commencing at 10:00 AM and concluding at 10:45 AM
- Total of 12,039 shareholders recorded as of the record/book closure date
- 39 shareholders attended the physical meeting (4 promoters and 35 public members)
- Special resolution proposed to consider a Scheme of Reduction of Share Capital
Hindustan Bio Sciences' Board approved a Scheme of Capital Reduction under Section 66 of the Companies Act to write off Rs 1.13 Cr of accumulated losses (out of total accumulated losses of Rs 1.22 Cr). The scheme reduces paid-up equity capital from Rs 2.05 Cr (1,02,50,800 shares of Rs 2 face value) to Rs 0.92 Cr (46,12,860 shares of Rs 2 face value) by cancelling 56,37,940 shares pro-rata. Subsequently, the remaining shares will be consolidated 5:1 from Rs 2 face value to Rs 10 face value, resulting in a final capital base of 9,22,572 equity shares of Rs 10 each (an effective ratio of 9 shares of Rs 10 for every 100 shares of Rs 2 held).
- 56,37,940 equity shares of Rs 2 face value will be cancelled and extinguished on a pro-rata basis.
- Paid-up capital reduces from Rs 2,05,01,600 to Rs 92,25,720, setting off Rs 1,12,75,880 against accumulated losses of Rs 1,22,41,849.
- Shares will be consolidated from Rs 2 to Rs 10 face value; shareholders will receive 9 equity shares of Rs 10 for every 100 shares of Rs 2 held.
- Total outstanding shares shrink from 1,02,50,800 to 9,22,572 shares of Rs 10 each without altering relative percentage shareholding.
Hindustan Bio Sciences has scheduled a Board of Directors meeting on August 31, 2026, to consider and approve a draft Scheme of Reorganization/Rearrangement of Share Capital. The Board will also review the revised notice convening the company's 34th Annual General Meeting (AGM). In compliance with SEBI insider trading regulations, the trading window is closed from August 27, 2026, until 48 hours following the meeting. The micro-cap company currently operates with a market capitalization of ~Rs 7 Cr and a net worth of Rs 1 Cr.
- Board meeting convened for August 31, 2026, to consider a draft Scheme of Reorganization/Rearrangement of Share Capital.
- Board to review and approve the revised notice for the 34th Annual General Meeting.
- Trading window closed from August 27, 2026, until 48 hours post-meeting conclusion.
Hindustan Bio Sciences reported a complete halt in operational revenue for the quarter ended June 30, 2026, recording Rs 0.00 compared to Rs 32.19 Lakhs in the same period last year. The company posted a net loss of Rs 11.29 Lakhs, a sharp decline from the Rs 1.40 Lakh profit recorded in Q1 FY26. Total expenses of Rs 11.29 Lakhs were primarily driven by employee benefits and administrative costs, despite no trading activity. With a high debt-to-equity ratio of 2.83 and very low promoter holding of 12.2%, the lack of revenue is a significant concern for solvency.
- Revenue from operations dropped to Rs 0.00 from Rs 32.19 Lakhs in the year-ago quarter
- Net loss for the quarter stood at Rs 11.29 Lakhs versus a profit of Rs 1.40 Lakhs YoY
- Employee benefit expenses remained steady at Rs 5.72 Lakhs despite zero revenue generation
- The company's 34th Annual General Meeting (AGM) is scheduled for September 30, 2026
- Total comprehensive loss for the period matched the net loss at Rs 11.29 Lakhs
Hindustan Bio Sciences reported a severe operational downturn for the quarter ended June 30, 2026, recording zero revenue from operations compared to Rs 32.19 lakhs in the same period last year. The company posted a net loss of Rs 11.29 lakhs, a sharp reversal from the Rs 1.40 lakhs profit in Q1 FY26. Total expenses of Rs 11.29 lakhs were primarily driven by employee benefits (Rs 5.72 lakhs) and other administrative costs. With a market cap of only Rs 7 Cr and a high debt-to-equity ratio of 2.83, the lack of revenue is a significant concern for solvency.
- Revenue from operations fell to Rs 0.00 lakhs from Rs 32.19 lakhs in the year-ago quarter
- Net loss for the quarter stood at Rs 11.29 lakhs compared to a profit of Rs 1.40 lakhs YoY
- Employee benefit expenses remained steady at Rs 5.72 lakhs despite zero revenue
- The 34th Annual General Meeting (AGM) is scheduled for September 30, 2026
- Company continues to operate in a single segment: Trading of Pharmaceuticals
Hindustan Bio Sciences has scheduled a board meeting on July 31, 2026, to consider and approve the unaudited financial results for the quarter ended June 30, 2026. The company is currently in a fragile financial state with a small market capitalization of Rs 7 Cr and a high Debt-to-Equity ratio of 2.83. Investors should note that the company reported zero revenue in the most recent March 2026 quarter, making this upcoming earnings release critical for assessing business continuity. Promoter holding remains low at 12.19%, providing limited skin in the game.
- Board meeting scheduled for July 31, 2026, to approve results for the quarter ended June 30, 2026
- Company reported zero revenue and a net loss of Rs 0.12 Cr in the preceding March 2026 quarter
- Promoter holding is stagnant at a low level of 12.19% as of June 2026
- TTM revenue stands at just Rs 1 Cr against a debt of Rs 2 Cr
Financial Performance
Financial analysis data not yet available for this company.
Operational Drivers
Operational analysis data not yet available for this company.
Strategic Growth
Strategic growth analysis not yet available for this company.
External Factors
External factors analysis not yet available for this company.
Regulatory & Governance
Regulatory analysis not yet available for this company.
Risk Analysis
Risk analysis not yet available for this company.
